3 ms·
There's a pretty good Frontline about this...I didn't see this fact listed in the article, but another huge problem is that it's generally not profitable for bi
by tombert 10y ago
There's a pretty good Frontline about this...I didn't see this fact listed in the article, but another huge problem is that it's generally not profitable for big medicine corporations to research new antibiotics, which means that for the time-being, we're stuck with our current regime.
- tremon 10y agoIt wasn't profitable to research the old antibiotics either. They were developed with government money.
- Fomite 10y agoThere is active research funded by large pharmaceutical companies in developing new antibiotics. Merck bought Cubist Pharmaceuticals for a reason.
- radus 10y agoMerck followed the purchase with firing a large chunk of Cubist's researchers. It's more likely that they purchased Cubist for Dapto, a proven winner and billion dollar drug, and maybe for their pipeline. I wouldn't hold my breath for Merck to follow through on the research beyond trawling through whatever Cubist had in development already.
- Fomite 10y ago"Merck bought a company for their already successful antibiotic and the others they had in the pipeline" hardly undermines the notion that there's still money in antibiotic development. And they're still funding studies for Fidaxomicin.
- pdabbadabba 10y agoI find this implausible. Surely pharmaceutical companies are as aware as anyone of the growing antibiotic-resistance problem and know that there will likely be a return on their investments in new antibiotic research. Sure, these companies sometimes exhibit a bias towards short-term gains, but they also aren't run by morons. And if they are run by morons, I see some great start-up opportunities...
- radus 10y agoThe reason they are not profitable is because generally antibiotics are only taken for short time periods. Additionally, it is almost certain that new antibiotics will be obsoleted by the emergence of resistance. Spending hundreds of millions of dollars on bringing a drug to market is already a risky proposition, even more so when your drug will be consumed in low quantities and may be useless before the patent even expires.